Selective RET inhibitors as selpercatinib and pralsetinib have shown high response rates and improved tolerability in RET-mutated thyroid cancers, while larotrectinib and entrectinib target NTRK fusions across tumor types, including rare thyroid cancer subtypes [17]. The gene discussed is RET; the disease is thyroid gland carcinoma.